242 Wythe Ave #4, Brooklyn, NY 11249


Indaco Venture Partners SGR expands its area of investment activity in biotech and drug development with a dedicated Fund and an experienced team in the sector.

Indaco Bio will have a particular focus on Italy, and will also selectively invest internationally. The fund will invest in startups for the development of innovative drugs and therapies.

Investors at first closing include: EIF – European Investment Fund, CDP Venture Capital SGR, Intesa Sanpaolo, Quaestio SGR, Inarcassa.

Milan, 17th May 2022 – Indaco Venture Partners SGR, one of Italy’s leading independent venture capital operators, today announces the first closing at 95 million euros of the new Indaco Bio Fund  entirely dedicated to the development of innovative pharmacological therapies.

The pandemic has increased society’s awareness of how important the availabilty  of effective, adequate and safe medicines is. In addition, this phenomenon has accelerated investors’ interest in this sector, where there are still unexplored development opportunities and technologies. In turn, this will accelerate bringing new treatments to the market. 

The capital raised will be invested to support companies and entrepreneurs engaged in the development of innovative drugs (molecules, gene and cell therapies, vaccines, etc.) intended for various clinical indications, with particular attention to those related to the central nervous system, oncology, ophthalmology, metabolic- and infectious-diseases. 

The Fund mission is to support the drug development from the preclinical to the clinical stages. Investments will be mostly in Italian companies, but also selectively in Europe, North America and Israel. The fund’s strategy will provide support both to early-stage startups, born from scientific research laboratories, and to the financing of series A and subsequent rounds. 

The European Investment Fund (EIF), CDP Venture Capital SGR through the Technology Transfer fund, Intesa Sanpaolo, Quaestio SGR, and Inarcassa invested in the first closing of Indaco Bio Fund. 

The Indaco Bio team is composed of Elizabeth Robinson, Vice Chairman of Indaco SGR and key-manager of Indaco Bio, Davide Turco, Managing Director of Indaco SGR, key-manager of Indaco Bio, and Giovanni Rizzo, Partner and key-manager of Indaco Bio. 

Pharmaceutical research and in particular that in the field of biotechnology are now the focus of public attention. For this reason, investments in science, research and innovation become, today more than ever, a fundamental engine to strengthen the nascent entrepreneurial realities and to attract further funding. We must consolidate and increase the economic levers to trigger a virtuous circle able to make the most of the excellence in life science basic research in Italy” – commented Elizabeth Robinson, co-founder and Vice Chairman of Indaco SGR.

“The launch of Indaco Bio Fund is the culmination of a project that we have been cultivating for some time and that finds its basis in the investments already started in the sector by our Atlante Seed fund. Indaco Bio Fund consolidates the role of Indaco SGR as a venture capital manager able to develop a plurality of specialized platforms that deepen and expand Indaco’s ability to contribute to the growth of Italian startups with high potential and international reach” – commented Davide Turco, co-founder and managing director of Indaco SGR.

Italy excels in scientific academic research in the biotechnology sector. However, to create safe and effective drugs it is necessary to exploit this research through increasingly consolidated experiences and skills. In Italy we are witnessing the creation of an important drug development ecosystem and Indaco Bio Fund, in collaboration with national and international players, will be able to make available its expertise and experience to support the development of innovative pharmacological therapies for patients – commented Giovanni Rizzo, Partner and key-manager of the Indaco Bio Fund.

For more information

Indaco Venture Partners SGR

Indaco Venture Partners SGR (“Indaco SGR”) is one of the largest Italian independent venture capital managers with 

over 350 million euros of capital invested through six funds including Indaco Venture I – launched in 2018 – which raised 134 million euros. 

Indaco invests in companies that innovate in the field of electronics and robotics, digital, medtech and now biotech /pharma. The SGR’s focus is mainly on the Italian market, but it also makes investments in Europe, the United States, Canada and Israel. www.indacosgr.com

For more information

Press Office 


Eleonora Meneghelli/Alberto Colombini